Health Protection Agency
Patient Information Leaflet
HPV Vaccination Study
Full title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving CervarixTM or GardasilTM Human Papillomavirus vaccines
The First International HPV Vaccine Information Clearinghouse
Health Protection Agency
Patient Information Leaflet
HPV Vaccination Study
Full title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving CervarixTM or GardasilTM Human Papillomavirus vaccines
Ethiopian Review
August 30th, 2010 at 12:34 am |
Waterford Today
Ireland
Cervical cancer is the second leading cause of death from cancer world-wide. (Bridges, 2008) It is also the leading cause of cancer related deaths in the developing countries. (National Cervical Cancer Coalition) Ireland has one of the highest cervical cancer death rates in Western Europe and this rate is increasing by 1.5% per year. (The Irish Cancer Society, 2008 and Condon, D. 2005.) The implementation of a nationwide cervical screening programme for all women aged 25-60 years is called upon- urgently. Such a programme would reduce the incidence of cervical cancer by 80 %.( I.C.S. 2007) In the meantime the introduction of the Gardasil injection targeted initially towards the 9-26year old paves the way for reductions in the current trends for the future.
Journal of Clinical Oncology, Vol 17, Issue 5 (May), 1999: 1391
© 1999 American Society for Clinical Oncology
ABSTRACT
PURPOSE: To evaluate the feasibility of detecting human papillomavirus E6 (HPVE6) gene mRNA in the peripheral blood of
patients with locally advanced cervical cancer, and the relationship of the circulating HPV viral–specific mRNA with clinicopathologic factors and prognosis of locally advanced cervical cancer.
vactruth.com
Christina England
06/28/2010
If you dangle a nice juicy carrot in front of many of the world’s leading experts advising the governments on vaccine policies, they will accept the carrot like any other ‘ass’. This has been proven over and over, however, agreeing to use little girls in experiments for the HPV vaccine Gardasil, is stooping about as low as anyone could go. This, however, is exactly what one group of experts from Norway have done. According to the Norwegian newspaper the VG NETT in their report Fikk betalt av vaksineprodusent – VG Nett om Helse og medisin the Norwegian experts received money from Merck and then advised their government on the HPV vaccine Gardasil, which at the time was only in it’s experimental stages, thus putting their own financial gain above the lives of the innocent children of Norway.
Medical News Today
Article Date: 28 Aug 2010 – 0:00 PDT
Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.